Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial
Article 2023 en
Authors
AT
Azita H. Talasaz
PS
Parham Sadeghipour
HB
Hooman Bakhshandeh
Abstract
1 min read
Atorvastatin 20 mg compared with placebo did not significantly reduce the 90-day composite of death, treatment with ECMO, or venous/arterial thrombosis. However, the point estimates do not exclude a potential clinically meaningful treatment effect, especially among patients who presented within 7 days of symptom onset (NCT04486508).
Mohammad Bosaeed, Ahmad M. Alharbi, Mohammad H. Hussein, Mohammed Abalkhail, Khizra Sultana, Abrar Musattat, Hajar AlQahtani, Majid M. Alshamrani, Ebrahim Mahmoud, Adel Alothman, Abdulrahman Alsaedy, Omar Aldibasi, Khalid Alhagan, Abdullah Mohamed Asiri, Sameera Aljohani, Majed Al-Jeraisy, Ahmed Alaskar
Andrew R. Pettitt, Nagesh Kalakonda, Fotis Polydoros, M. Bickerstaff, Geetha Menon, Sarah E. Coupland, M Oates, Ke Lin, Chris Pocock, Stephen Jenkins, Anna Schuh, Farooq Wandroo, Sal Rassam, Andrew Duncombe, Matthew Jenner, P. Cervi, Shankara Paneesha, Maadh Aldouri, Christopher P. Fox, C. Knechtli, Michael R Hamblin, ,
Discussion(0)
No comments yet. Be the first to comment.